

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
07 November 2024 (07.11.2024)



(10) International Publication Number
WO 2024/229087 A1

(51) International Patent Classification:

C07D 498/22 (2006.01) C07D 231/10 (2006.01)
A61K 31/4162 (2006.01) C07D 519/00 (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/US2024/027195

(22) International Filing Date:

01 May 2024 (01.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/463,498	02 May 2023 (02.05.2023)	US
63/627,624	31 January 2024 (31.01.2024)	US
63/636,734	20 April 2024 (20.04.2024)	US

(71) Applicant: **BLOSSOMHILL THERAPEUTICS, INC.**
[US/US]; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US).

(72) Inventors: **CUI, Jingrong Jean**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **RUI, Eugene
Yuanjin**; 3525 John Hopkins Court, Suite 100, San Diego,
California 92121 (US). **ROGERS, Evan W.**; 3525 John
Hopkins Court, Suite 100, San Diego, California 92121
(US). **SARKAR, Anindya**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **ZHAI, Day-
ong**; 3525 John Hopkins Court, Suite 100, San Diego, Cali-
fornia 92121 (US). **DENG, Wei**; 3525 John Hopkins Court,
Suite 100, San Diego, California 92121 (US). **UNG, Jane**;
3525 John Hopkins Court, Suite 100, San Diego, California
92121 (US).

(74) Agent: **LEWALLEN, Daniel M.**; BARNES & THORN-
BURG LLP, 11 South Meridian Street, Indianapolis, Indi-
ana 46204 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

WO 2024/229087 A1

(54) Title: EGFR INHIBITORS FOR TREATING DISEASE

(57) Abstract: The present disclosure relates to compounds targeting kinases such as EGFR, pharmaceutical compositions containing the compounds, and methods of using such compounds to treat disease, such as cancer.